Respiratory syncytial virus F protein epitopes
US10016496B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jan 31, 2014 |
| Grant date | Jul 10, 2018 |
| Priority date | — |
| Expiry date | Jan 31, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2760/18534
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Respiratory Syncytial Virus is a common cold virus belonging to the family of paramyxovirus. RSV is virulent, easily transmissible and the most common cause of lower respiratory tract disease in children of less than 2 years of age. Up to 98% of children attending day care will be infected in a single RSV season. Between 0.5% and 3.2% of children with RSV infection require hospitalization. Approximately 90,000 hospital admissions and 4500 deaths per year were reported in United States. Major risk factors for hospitalization due to RSV are premature birth, chronic lung disease, congenital heart disease, compromised immunity, and age younger than 6 weeks in otherwise healthy children.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.